Since 1971, the landscape of drug research in the United States has been drastically altered, with severe restrictions placed on the study of substances deemed “most dangerous.” The Controlled Substances Act (CSA), ostensibly implemented for public protection, has instead created a system that inadvertently benefits pharmaceutical companies by maintaining their monopoly on drug manufacturing and distribution.